Andere Sprachen SELLAS Life Sciences Group, Inc.

Aktien

A2PU3T

US81642T2096

SLS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 30.04.2024			% 5 Tage	% 1. Jan.
1.24 ^USD	+2.48%		-23.93%	+16.98%

29.04.	SELLAS Life Sciences Group, Inc. gibt positive Empfehlung des unabhängigen Datenüberwachungsausschusses nach Abschluss der Rekrutierung in der Phase-3-Studie REGAL bekannt	CI
28.03.	SELLAS Life Sciences Group, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	29.04.
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	29.04.
North American Morning Briefing : Powell Awaited -2-	03.04.
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update	28.03.
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study	26.03.
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML	26.03.
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET	19.03.
Sector Update: Health Care Stocks Ease Late Afternoon	15.03.
Top Midday Decliners	15.03.
Sector Update: Health Care Stocks Softer Friday Afternoon	15.03.
Sellas Life Sciences Launches $20 Million Direct Offering, Private Placement -- Shares Fall	15.03.
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	15.03.
SELLAS Life Sciences Group, Inc. announced a financing transaction	15.03.
SELLAS Life Sciences : Material Event - Form 8-K	11.03.
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships	08.03.
SELLAS Life Sciences Group, Inc. Announces Executive Changes	08.03.
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference	01.03.
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time	29.02.
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget	06.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen SELLAS Life Sciences Group, Inc.

Aktien

A2PU3T

US81642T2096

SLS

Andere Sprachen

Filter